Fenwick & West represented Terns Pharmaceuticals Inc., a global biopharmaceutical company focused on discovering and developing molecularly targeted, oral, small-molecule drugs to treat NASH and cancer, in its $80 million Series B financing. Vivo Capital and OrbiMed led the round with participation from new investor Decheng Capital and existing investor Lilly Asia Ventures.
The financing will support the pipeline development of clinical and preclinical NASH candidates to treat NASH and cancer. More information about Terns’ $80 million Series B financing can be obtained from the company announcement.
The Fenwick transaction team was led by corporate lawyers Matt Rossiter, James Li, David He and Christina Zhao; and tax lawyer Will Skinner.